Pfizer will provide up to 6 million courses of its antiviral COVID-19 treatment, Paxlovid, for the Global Fund, the pharmaceutical company said Sept. 22.
The Global Fund focuses on offering resources to low- and middle-income countries. In this fund, low- and lower-middle-income countries will pay a nonprofit price for Paxlovid and upper-middle-income countries will pay an undisclosed but discounted price.